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Article category – Research Article 
 
Novelty and Impact 
Osteosarcoma (OS) can be a fatal disease. MicroRNAs (miRNAs) play crucial roles in 
osteosarcomagenesis. In this study, we identify miR-16-1* and miR-16-2* as strong 
tumor suppressors and anti-metastatic genes in OS. This is the first report 
demonstrating tumor suppressive functions of passenger strands of these miRNAs in 
OS. Given that MIR-16-1 is located in 13q14 region that is commonly deleted in several 
human malignancies, our findings shed light on oncogenic mechanisms triggered by 
13q14 deletion.  
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Abstract 
Osteosarcoma (OS) is an aggressive malignancy affecting mostly children and 
adolescents. MicroRNAs (miRNAs) play important roles in OS development and 
progression. Here we found that miR-16-1* and miR-16-2* “passenger” strands as well 
as the “lead” miR-16 strand possess strong tumor suppressive functions in human OS. 
We report different although strongly overlapping functions for miR-16-1* and miR-16-2* 
in OS cells. Ectopic expression of these miRNAs affected primary tumor growth, 
metastasis seeding, and chemoresistance and invasiveness of human OS cells. Loss-
of-function experiments verified tumor suppressive functions of these miRNAs at 
endogenous levels of expression. Using RNA immunoprecipitation (RIP) assays, we 
identify direct targets of miR-16-1* and miR-16-2* in OS cells. Furthermore, validation 
experiments identified FGFR2 as a direct target for miR-16-1* and miR-16-2*. Overall, 
our findings underscore the importance of passenger strand miRNAs in 
osteosarcomagenesis.   
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Introduction 
Osteosarcoma (OS) is the most common form of bone and joint cancer which is 
responsible for about 9% of cancer deaths in children and adolescents ages 10-24 1. 
Noteworthy, OS has a very complex karyotype with many nonrecurrent genetic 
abnormalities 2. Recently, it has been proposed that OS consists of many genetically 
different entities with different metastatic potential which occur due to OS-specific p53-
independent preexisting genomic instability 3. Hence, genetic complexity of this 
malignant disease probably underlies the plateau in 5-year survival rate, which occurred 
in the middle of 1980s 4, with a third of all OS patients still dying during the first 5 years 
after diagnosis mainly due to pulmonary metastases 5. Moreover, metastases at 
diagnosis lead to further decrease in 5-year survival to less than one third of OS 
patients 6-8. Thus, better understanding of various osteosarcomagenesis molecular 
mechanisms is required for development of better treatments for this deadly malignant 
disease. 
MicroRNAs (miRNAs) are small RNA molecules which length is typically 21-23 
nucleotides although it may vary from 16 to 27 nucleotides 9. They mostly regulate 
protein-coding genes expression at the post-transcriptional level through mRNA 
translation repression and consequent degradation 10. Most of miRNA genes are 
transcribed by DNA-dependent RNA polymerase II and primary transcripts (pri-miRNAs) 
are further processed by the microprocessor complex in miRNA precursors (pre-
miRNAs) with hairpin stem-loop structure, which are exported from the nucleus to the 
cytoplasm. Then, cytoplasmic RNase III Dicer cleaves pre-miRNAs which results in 
miRNA duplexes. Typically, one strand of a miRNA duplex is bound by argonaute 
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proteins, loaded on miRNA-induced silencing complex (miRISC), and guides the 
miRISC to target mRNAs. This strand is called “lead” or “guide” strand. The other strand 
is usually mostly degraded and presented in the cell at a much lower level. This strand 
is called “passenger” or “star” strand and designated as miR* 11. 
miRNAs expression deregulation as a driving force in oncogenesis is an established 
concept supported by massive research data 12. Involvement of miRNAs particularly in 
osteosarcomagenesis is also supported by accumulating evidences 13. Our group have 
identified a set of miRNAs, which expression is altered in OS samples in comparison 
with healthy bones 14. We further demonstrated that miR-27a/miR-27a* pair promotes 
OS metastasis at least partly through targeting of CBFA2T3 15. Pro-metastatic 
properties of “passenger” miR-27a* strand, which is expressed at much lower level than 
the “lead” miR-27a strand, were of particular interest for us. Indeed, there is mounting 
evidence that so-called “passenger” miRNA strands are involved in oncogenesis 16-21. 
This prompted us to study a possible involvement of other “passenger” miRNAs in 
osteosarcomagenesis. Noteworthy, miR-16, which originates from two loci, MIR-16-1 
(chromosome 13) and MIR-16-2 (chromosome 3) (22 and Fig 1A), in the human 
genome, is down-regulated in OS samples versus healthy bones 14. Although MIR-16-1 
and MIR-16-2 loci both encode the same miR-16 “lead” strand they encode different 
“passenger” strands – miR-16-1* and miR-16-2*, respectively. Interestingly, we found 
that miR-16-2* expression is also down-regulated in OS samples versus healthy bones 
14
. We, therefore, decided to test miR-16-1* and miR-16-2* functions in 
osteosarcomagenesis. Here, we report that miR-16-1*, miR-16-2* as well as miR-16 
possess tumor suppressive and anti-metastatic functions in human OS cells. 
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Materials and Methods 
Cell lines and cell culture 
HOS, KHOS, U2OS, SAOS2, MG63, and 143B cells were obtained from American Type 
Culture Collection (ATCC, Manassas, VA) and were maintained in RPMI medium 
complemented with 10% heat-inactivated FBS, 100 U/ml penicillin, and 100 mcg/ml 
streptomycin. Where it is indicated in the text cells were cultured without antibiotics. 
HEK-293T cells were obtained from Fisher Scientific and were maintained in DMEM 
medium complemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml 
penicillin, and 100 mcg/ml streptomycin. 
 
Colony formation assay 
HOS or KHOS cells (1.5x102) were seeded per a 10cm tissue culture plate in RPMI 
medium complemented with 10% heat inactivated FBS, 100 U/ml penicillin and 100 
mcg/ml streptomycin. All experiments were conducted in four replicates. Colonies were 
fixed with ethanol, stained with Giemsa and counted in 9 days after seeding. 
 
Soft agar colony formation assay 
6-well plates with 1.5 ml of 0.5% bottom agar in RPMI complemented with 10% heat-
inactivated FBS, 2 g/L sodium bicarbonate, 2 mM L-glutamine, 100 U/ml penicillin, and 
100 mcg/ml streptomycin were prepared by mixing even amounts of double 
concentrated RPMI containing double concentrated additives and 1% melted agar 
solution in water at 40ºC. The bottom agar was left to solidify for 30 minutes at room 
temperature. Cells were added to prewarmed to 30ºC double concentrated RPMI with 
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double concentrated additives and mixed with even amount of cooled to 39ºC 0.7% 
melted agar solution in water. The obtained 0.35% melted top agar solution in RPMI 
with additives containing cells was plated in prepared wells of 6-well plates with bottom 
agar. 1.5 ml of the top agar containing one thousand cells were plated in each well. 0.5 
ml of RPMI medium with additives were added to each well after the top agar was 
solidified. Each experiment was conducted in triplicates. 0.2-0.3 ml of fresh RPMI 
medium with additives were added to each well twice a week in order to avoid drying of 
agar. Twenty one days after plating, the grown colonies in agar were fixed and stained 
with 0.01% crystal violet solution in 10% ethanol in water. Then wells were washed 6 
times with water and colonies were counted. 
 
Chemoresistance assays 
U2OS (10X103) or HOS (5X103) cells were plated in each well of 96-well plates. 
Cisplatin or doxorubicin treatments were started 24 hours after plating by complete 
replacing of medium in wells with 200 mcl of medium containing required concentration 
of the drug. Each drug concentration was tested in triplicates. Cells survival was 
quantified by an XTT-based assay (Biological Industries, USA) according to the 
manufacture’s protocol in 48 hours after the drug adding. Survival of untreated cells was 
taken as 100% for each type of cells. 
For experiments with synthetic microRNA mimics, U2OS cells in a well of 6-well plates 
were transfected with 200 pmoles of a double-stranded synthetic microRNA mimic and 
17.5 mcl of Lipofectamine 2000 transfection reagent (Thermo Fisher Scientific, USA) 
according to the manufacturer’s instructions. Cells were in RPMI medium with 10% 
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heat-inactivated serum but without antibiotics and at 90% confluence. 6-8 hours after 
transfection the medium was changed for fresh one without antibiotics. Twenty four 
hours after transfection cells were seeded in wells of 96well plates (ten thousand cells 
per a well) and treatments with drugs were started 16 hours later.  
 
Matrigel invasion assay 
HOS cells at 50-70% confluency were detached from culture plates by incubation in 1 
mM EDTA in PBS. Two hundred thousand cells were placed in the upper part of a blind 
well chemotaxis chamber in serum-free RPMI medium. The bottom part of the blind well 
chemotaxis was filled with RPMI medium complemented with 10% heat-inactivated 
FBS, 100 U/ml penicillin, and 100 mcg/ml streptomycin. Upper and bottom parts of the 
blind well chemotaxis chamber were separated by a Matrigel-coated membrane with 
size of pores 8 mcm. Invasion assays were conducted for 4 hours in triplicates. The 
upper surfaces of membranes were wiped with a cotton swab in order to remove non-
invaded cells. Then invaded cells were fixed and stained with Diff-Quick System (Dade 
Behring, Inc., UK). Photos of ten random fields for each membrane were taken and 
invaded cells were counted. 
 
Tumorigenic and metastatic assays in NOD/SCID mice 
All experiments with NOD/SCID mice were conducted in agreement with guidelines of 
the Institutional Animal Care and Use Committee of The Hebrew University of 
Jerusalem under approved protocols. Four-six weeks aged NOD/SCID male mice were 
used for experiments. One million HOS cells or five hundred thousand KHOS cells were 
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subcutaneously (SC) injected in 100 mcl of RPMI medium in each flank of a NOD/SCID 
mouse. Each mouse was injected in both, right and left, flanks. Measurements of linear 
tumors’ sizes were conducted once or twice a week after tumors appeared. Tumors’ 
volumes were estimated as (a*b^2)/2 where a is the longest linear size and b is the 
smallest linear size. The experiment with HOS clones overexpressing miR-16, miR-16-
1* or miR-16-2* was conducted for 23 days. The experiment with KHOS cells 
overexpressing miR-16 or miR-16-2* was conducted for 64 days. The experiment with 
KHOS cells overexpressing Contr-Sp, miR-16-Sp, miR-16-1*-Sp or miR-16-2*-Sp was 
conducted for 48 days. Tumors’ masses were measured when mice were euthanized 
and open. Pictures of fluorescent EGFP-positive metastatic nodules in lungs were taken 
in the experiment with EGFP-positive KHOS cells overexpressing microRNA sponges. 
Then numbers of metastatic nodules in each lung were counted. 
Orthotopic intratibial (IT) injections were conducted in right rare legs of four-six weeks 
old NOD/SCID mice. Five hundred thousand HOS cells in 20 mcl of 25% growth factors-
reduced matrigel in RPMI were injected each time. IT injected NOD/SCID mice were 
observed for 31 days. Then mice were euthanized and all measurements were 
conducted. Tumors’ volumes were estimated as (a*b^2)/2 where a is the longest linear 
size and b is the smallest linear size. 
 
Statistical analysis 
Statistical significance of all pair-wise comparisons was assessed by two- or one-sided 
Student’s t-test. If data variability was too large for Student’s t-test then the Rank-Sum 
statistics was applied. Adjusted p-value was applied to estimate statistical significance 
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of finding in the RIP-Seq experiment. P-value adjustment was conducted by the 
Benjamini-Hochberg method. Further details can be found in the Supporting Information 
for this article online. Statistical significance of the correlations investigated was 
estimated by Spearman Correlation. 
Other materials and methods can be found in the Supporting Information for this 
article online. 
 
Results 
MiR-16, miR-16-1* and miR-16-2* expression in OS samples and OS cell lines 
We found earlier that expression of miR-16 and miR-16-2* is downregulated in OS 
versus healthy bone while miR-16-1* expression was undetectable 14. All these miRNAs 
originate from two loci – MIR-16-1 and MIR-16-2 (Fig 1A). The lead miR-16 strand is 
identical for both loci while the miR-16-1* strand is specific for the MIR-16-1 locus and 
the miR-16-2* strand is specific for the MIR-16-2 locus (Fig 1A). MiR-16-1* and miR-16-
2*, which have been mostly considered so far as passenger strands or miR-16 
biogenesis byproducts, have very similar but somewhat different sequences (Fig 1B). 
There is also one mismatch between miR-16-1* and miR-16-2* sequences in the seed 
region (Fig 1B), which should lead to different binding sites for these miRNAs.  
Nothing has been studied about functions of the passenger miR-16-1* and miR-16-2* 
strands, and we decided to address their possible roles in osteosarcomagenesis. First, 
we addressed abundance of these miRNAs in OS cells and assayed miR-16, miR-16-1* 
and miR-16-2* expression in several OS cell lines by TaqMan Real-Time PCR (Suppl 
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Fig 1). MiR-16-1* expression was out of the quantitative range for this assay (Suppl Fig 
1K). MiR-16 expression varied from 5.5 thousand to 28.5 thousand molecules per cell 
(Suppl Fig 1G), which is similar to earlier published data for mouse organs and embryo 
23
. MiR-16-2* expression varied from ~320 to ~850 molecules per cell (Suppl Fig 1H) 
and the ratio of miR-16 expression to miR-16-2* expression was in the range from 18 to 
80 (Suppl Fig 1J). 
 
MiR-16, miR-16-1* and miR-16-2* overexpression suppresses OS cells survival  
In order to address functional roles of miR-16, miR-16-1* and miR-16-2* in OS we 
overexpressed these miRNAs in HOS cells. Since HOS polyclonal cultures lose 
overexpression of these miRNAs too quick (data are not shown) we obtained HOS 
clones for overexpression of each miRNA (Fig 2A). 
Results of colony formation and soft agar colony formation assays suggest that 
overexpression of any of these miRNAs – miR-16, miR-16-1*, or miR-16-2* – drastically 
reduces both colony formation ability and anchor-independent growth of HOS cells (Fig 
2B, C). Noteworthy, effects of miR-16-1* as well as miR-16-2* overexpression on HOS 
cells colony formation is much stronger than the effect of miR-16 overexpression (Fig 
2B). These data suggest that miR-16, miR-16-1* as well as miR-16-2* overexpression 
decreases HOS cells survival. 
Further we decided to check whether miR-16, miR-16-1* and miR-16-2* overexpression 
effects can be reproduced in another OS cell line. We chose KHOS cell line and were 
able to overexpress there miR-16 and miR-16-2* (Fig 2D) but not miR-16-1* (data are 
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not shown). Overexpression of miR-16 and miR-16-2* led to a dramatic decrease in 
KHOS colony formation ability (Fig 2E), which is consistent with our data for HOS cells 
(Fig 2B). We hypothesized that our inability to overexpress miR-16-1* was due to a very 
strong effect of miR-16-1* on KHOS cells survival and selection with puromycin kills 
KHOS cells overexpressing miR-16-1*. In order to overcome this obstacle, we subjected 
KHOS cells, which were infected with lentiviruses for overexpression of miR-16, miR-
16-1* or miR-16-2*, to colony formation assays immediately after infection without 
puromycin selection. Indeed, KHOS cells infected with miR-16, miR-16-1* or miR-16-2* 
had much reduced colony formation abilities in comparison to KHOS cells infected with 
empty lentivirus or parental KHOS cells (Fig 2F). Similar results were obtained for HOS 
cells (Fig 2F). Altogether, these findings suggest that products of MIR-16-1 and MIR-16-
2 loci have anti-survival effects in vitro. These findings are consistent with possible 
tumor suppressive functions of these miRNAs. 
 
MiR-16, miR-16-1* and miR-16-2* overexpression enhances apoptosis and 
chemosensitivity 
We also set to determine whether these miRNAs promote apoptosis of OS cells. 
Indeed, overexpression of miR-16, miR-16-1* or miR-16-2* increases the percentage of 
annexin V/PI staining suggesting that KHOS cells are undergoing apoptosis (Fig 3A, B).   
We next addressed the outcome of these miRNAs on chemosensitivity. To this end, we 
assessed effects of miR-16, miR-16-1* and miR-16-2* overexpression on HOS 
resistance to cisplatin and doxorubicin treatment. Remarkably, miR-16-2* 
overexpression but not miR-16-1* or miR-16 overexpression significantly sensitized 
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HOS cells to both cisplatin and doxorubicin treatments (Fig 3C, D). Curiously, the same 
miR-16-1* overexpressing clones in parallel colony formation assays formed even less 
number of colonies than corresponding miR-16-2* overexpressing clones (Fig 2B). 
These data suggest that despite of high similarity between miR-16-1* and miR-16-2* 
sequences these miRNAs possess different although overlapping functions. 
We also addressed the question whether synthetic miR-16, miR-16-1* and miR-16-2* 
mimics could affect OS cells resistance to cisplatin. We chose U2OS cell line for these 
experiments since this cell line is easy to transfect. Interestingly, all tested microRNAs – 
miR-16, miR-16-1* and miR-16-2*, sensitized U2OS cells to the cisplatin treatment with 
similar efficiencies (Fig 3E). This result suggests that at high level of overexpression of 
all tested miRNAs – miR-16, miR-16-1* and miR-16-2*, can efficiently sensitize OS cells 
to the cisplatin treatment. It also suggests that miR-16, miR-16-1* and miR-16-2* 
mimics could be beneficial to improve outcomes of the conventional OS chemotherapy, 
which includes combined treatment with cisplatin, doxorubicin and methotrexate 5. 
 
Endogenous miR-16, miR-16-1* and miR-16-2* expression effects OS cells 
chemoresistance in vitro 
In order to clarify whether miR-16, miR-16-1* and miR-16-2* endogenous expression 
effects chemosensitivity of OS cells we constructed miR-16, miR-16-1* and miR-16-2* 
sponges [SP] (Fig 4A) and overexpressed them in U2OS cells. Upon overexpression, 
miRNA sponges bind the corresponding miRNAs and sequester them from binding with 
their targets. Thus, miRNA sponges’ overexpression leads to functional inactivation of 
corresponding miRNAs 24. We subjected U2OS cells, which overexpress miR-16, miR-
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16-1* or miR-16-2* sponges, to the cisplatin and doxorubicin resistance assays. While 
none of these sponges had a consistent effect on doxorubicin resistance (data are not 
shown) overexpression of any of these sponges increased the resistance of U2OS cells 
to cisplatin (Fig 4B).  
We also conducted CRISPR-based knock-out of each MIR-16 locus separately and 
both of them together in U2OS cells (Suppl Fig 2). Knock-out of any of two MIR-16 loci 
separately increased resistance of U2OS cells to cisplatin and knock-out of both MIR-16 
loci increased resistance of U2OS cells to cisplatin treatment even stronger (Suppl Fig 
2E). These results are consistent with microRNA sponges data (Fig 4B), and suggest 
that endogenous miR-16, miR-16-1* as well as miR-16-2* expression is essential for 
sensitivity of OS cells to cisplatin treatment. 
 
MiR-16, miR-16-1* and miR-16-2* overexpression effects on OS cells 
tumorigenesis in NOD/SCID mice in vivo 
In order to assess effects of miR-16, miR-16-1* and miR-16-2* overexpression on the 
ability of human OS cells to form tumors in vivo, we subcutaneously injected cells from 
HOS clones overexpressing corresponding miRNAs into NOD/SCID mice. MiR-16-1* as 
well as miR-16-2* overexpression completely abolished the ability of HOS cells to form 
subcutaneous tumors in NOD/SCID mice while miR-16 overexpression significantly 
reduced HOS cells tumorigenesis upon their subcutaneous injection in NOD/SCID mice 
(Fig 5A-C). These results suggest that miR-16-1* as well as miR-16-2* possess 
stronger tumor suppressive activities than the lead miR-16 strand. 
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We also assessed the ability of selected HOS clones to form tumors in the orthotopic 
environment. MiR-16, miR-16-1* as well as miR-16-2* overexpression significantly 
reduced HOS tumorigenesis upon intratibial injections in NOD/SCID mice (Fig 5D, E). 
These results further support tumor suppressive properties of miR-16, miR-16-1* and 
miR-16-2* in OS cells in vivo. 
We also verified tumor suppressive functions of miR-16 and miR-16-2* in another OS 
cell line – KHOS. KHOS cells overexpressing miR-16 as well as miR-16-2* formed 
significantly smaller tumors upon subcutaneous injections of these cells in NOD/SCID 
mice than the control KHOS cells infected with the empty lentivirus (Fig 5F, G). 
Unfortunately, we could not conduct the same experiment with KHOS cells 
overexpressing miR-16-1* since these cells could not survive selection with puromycin 
(see above). Nevertheless, these data further support that miR-16 as well as miR-16-2* 
possess tumor suppressive properties in OS cells. 
 
MiR-16, miR-16-1* and miR-16-2* overexpression effects on OS cells invasion in 
vitro 
We also tested whether miR-16, miR-16-1* or miR-16-2* overexpression affects 
metastatic properties of OS cells such as invasion. Indeed, miR-16, miR-16-1* as well 
as miR-16-2* overexpression significantly reduced HOS cells invasion in vitro (Fig 6). 
This data suggests possible involvement these microRNAs in OS metastatic process. 
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Roles of endogenous miR-16, miR-16-1* and miR-16-2* expression in OS cells 
tumorigenesis and metastatic process upon subcutaneous injections of human 
OS cells in NOD/SCID mice in vivo 
Although overexpression data clearly indicated tumor suppressive functions of miR-16, 
miR-16-1* and miR-16-2* in OS cells it was unclear whether endogenous levels of these 
miRNAs affects tumorigenic and/or metastatic properties of OS cells. In order to clarify 
this question, we subcutaneously injected KHOS cells overexpressing sponges for 
these miRNAs into NOD/SCID mice. Overexpression of a sponge for any of these 
miRNAs led to an increase in the average primary tumor mass although it was not 
statistically significant (Suppl Fig 3A-C). Nevertheless, there was a significant increase 
in the number of lung metastases in KHOS cells overexpressing a sponge for any of 
these miRNAs in comparison to KHOS cells overexpressing the control miRNA sponge 
(Suppl Fig 3D,E). These data suggest that miR-16, miR-16-1* as well as miR-16-2* 
likely possess anti-metastatic activities in human OS cells in vivo at endogenous levels 
of expression.  
 
MiR-16, miR-16-1* and miR-16-2* direct targets in OS cells 
The preceding observation indicate anti-survival, pro-apoptotic, tumor suppressive and 
anti-metastatic functions of miR-16, miR-16-1* and miR-16-2* in human OS cells. 
However, molecular mechanisms underlying these functions of miR-16, miR-16-1* and 
miR-16-2* remained obscure. We therefore aimed to identify direct targets of these 
miRNAs which is essential for clarifying of the molecular mechanisms.  
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In order to achieve this aim, we chose an unbiased approach based on 
immunoprecipitation of argonaute proteins’ complexes, known as RIP, for RNA 
immunoprecipitation (Suppl Fig 4). Argonaute proteins are an indispensable part of 
microRNA-induced silencing complexes (mRISCs), which contain direct targets of all 
miRNAs. Hence, RNA from immunoprecipitated argonaute proteins’ complexes should 
contain all direct targets of all miRNAs. We assumed that overexpression of a particular 
miRNA should recruit more of its direct targets into mRISCs and hence 
immunoprecipitation of the argonaute proteins’ complexes should identify those direct 
mRNA targets. The outline of this approach is shown in supplementary Figure 4. 
In order to implement this approach, we transfected cells from HOS clones 
overexpressing corresponding miRNAs as well as control HOS cells with a mix of 
plasmids overexpressing FLAG- and MYC-tagged Ago1, Ago2, Ago3 and Ago4 
proteins. Then argonaute proteins’ complexes were immunoprecipitated by the FLAG-
tag and total RNA was purified from these immunoprecipitants. The purified total RNA 
was subjected to deep RNA sequencing. This experiment was conducted in biological 
triplicates for each microRNA (miR-16, miR-16-1* and miR-16-2*) and for the control 
HOS cells. Enrichment of every annotated RNA in the immunoprecipitated argonaute 
proteins’ complexes upon overexpression of each studied microRNA was evaluated 
(Suppl Table 1). 
In order to highlight the most promising candidate direct targets of the studied miRNAs 
we reanalyzed miRNA and mRNA expression data from our previous article 14. Indeed, 
expression of direct targets of a given miRNA, which expression is mostly regulated by 
this miRNA in OS cells, should inversely correlate with expression of this miRNA in OS 
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samples. Thus, we determined genes, which expression inversely correlates with miR-
16 (Suppl Table 2) and/or miR-16-2* (Suppl Table 3) expression in OS samples at RNA 
level. Overlaps of these genes with genes, which are enriched in argonaute proteins’ 
immunoprecipitants for miR-16 (Suppl Table 4) and for miR-16-2* (Suppl Table 5), 
represent the most promising candidate direct targets for these miRNAs. We further 
refined our sets of candidate direct targets based on presence of predicted binding sites 
for corresponding miRNAs (Suppl Tables 4 & 5). Unfortunately, we could not conduct 
similar analysis for miR-16-1* targets, since its expression was not technically 
detectable by miRNA microarrays in most OS and healthy bone samples 14.  
We chose 6 potential direct targets for miR-16 and 9 potential direct targets for miR-16-
2* based on our analysis (Suppl Table 6). We also chose one specific potential direct 
target for miR-16-1* (Suppl Table 6). We checked expression of these targets in HOS 
clones overexpressing corresponding miRNAs. Most of these genes were significantly 
upregulated in HOS clones overexpressing corresponding microRNAs at levels 
comparable to their enrichment in the immunoprecipitated argonaute proteins’ 
complexes (data are not shown). These data suggested that these genes were enriched 
in the immunoprecipitated argonaute proteins’ complexes solely due to upregulation of 
their expression. However, expression of 3 genes (FRAS1, MMP16 and IFI6) was not 
changed or changed weakly in HOS clones overexpressing corresponding miRNAs 
(Suppl Fig 5A-F). Thus, these genes are likely to be directly regulated at the level of 
translation by corresponding microRNAs. 
Verification of potential direct targets of studied miRNAs by Real-Time PCR suggested 
that increase in proportion of argonaute bound mRNA upon a miRNA overexpression 
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indicates that this mRNA is a direct target of the miRNA. Simple enrichment of a mRNA 
in argonaute immunoprecipitants upon a miRNA overexpression is frequently due to 
expression upregulation of this mRNA (data are not shown). Therefore, direct targets 
could be even among genes, which are depleted in argonaute immunoprecipitants upon 
a microRNA overexpression. In order to check this possibility, we made a list of targets, 
which expression is inversely correlated with miR-16-2* expression in OS samples and 
which are depleted in the immunoprecipitated argonaute proteins’ complexes upon miR-
16-2* overexpression (Suppl Table 7). We chose FGFR2 gene for a detailed study. 
FGFR2 is significantly depleted in argonaute immunoprecipitants upon miR-16-2* 
overexpression (Suppl Tables 1, 7), FGFR2 expression inversely correlates with miR-
16-2* expression in OS samples (Suppl Tables 5, 7) and FGFR2 has predicted binding 
sites for miR-16, miR-16-1* and miR-16-2* (Suppl Table 6). In addition, FGFR2 is 
frequently activated and/or overexpressed in gastric cancer 25, a potential target for 
cancer therapy 26, involved in OS metastasis 27 and its mutations lead to inherited 
craniofacial malformation syndromes, which are associated with bone abnormalities 25. 
Interestingly, a proportion of argonaute-bound FGFR2 mRNA is significantly increased 
in miR-16 overexpressing HOS cells and not changed in miR-16-2* overexpressing 
HOS cells (Suppl Fig 5G, H). However, Ct values for FGFR2 from miR-16-2* 
overexpressing HOS cells were very high and the results were not quantitative. Hence, 
we cannot conclude whether the proportion of argonaute-bound FGFR2 mRNA is 
increased in miR-16-2* overexpressing HOS cells. To validate whether FGFR2 is a 
direct target of miR-16 and its associated passenger strands, we cloned its 3'UTR 
containing miRNA-responsive elements into the pGL3 vector downstream of the firefly 
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luciferase open reading frame and assessed the reporter activity in control, miR-16-1*-
overexpressing and miR-16-2*-overexpressing HOS clones. The luciferase activity of 
3’UTR was markedly reduced by miR-16-1/2* overexpression as compared to control 
cells (Suppl Fig 5I).  Moreover, miR-16, miR-16-1* as well as miR-16-2* overexpression 
leads to increase in Akt Ser473 phosphorylation (Suppl Fig 5J) that is consistent with 
PI3K/Akt pathway up-regulation in FGFR2 overexpressing osteoblasts 28. Altogether, 
these results suggest that miR-16 passenger strands could have overlapping targets 
hence contributing to OS development and progression.  
 
Discussion 
Here, we have provided evidences that miR-16-1* as well as miR-16-2* “passenger” 
strands function as tumor suppressors in OS. Their tumor suppressive effects as strong 
or even stronger than tumor suppressive effects of the “lead” miR-16 strand in human 
OS cells. These miRNAs effect both, OS primary tumorigenesis and metastasis. They 
have anti-survival and pro-apoptotic action in human OS cells and also reduce 
invasiveness and chemoresistance of human OS cells. This is the first report of any 
function for miR-16-1* and/or miR-16-2*. Although anti-metastatic properties of miR-16-
1* in gastric cancer cells were reported earlier by Wang T and his co-workers 29, it was 
not sufficiently detailed and explored as in our study. In fact, Wang T et al 
overexpressed miR-16-1 precursor for all functional experiments and did not check for 
miR-16 overexpression 29. Since miR-16-1* precursor overexpression is expected to 
lead to overexpression of both, the ”lead” miR-16 and the “passenger” miR-16-1*, 
strands (Fig 2A), then, it is not clear which strand caused functional effects in gastric 
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cancer cells 29. Noteworthy, our data also indicate that miR-16-1* and miR-16-2* have 
different although strongly overlapping functions. In addition, our results suggest that 
FGFR2 is a direct target of miR-16-1* as well as miR-16-2*. This sheds some light on 
mechanisms underlying miR-16-1* and miR-16-2* tumor suppressive functions since 
FGFR2 is frequently activated in gastric cancer 25, promotes metastasis in OS 27, its 
aberrant activation leads to inherited craniofacial malformation syndromes, which are 
associated with bone abnormalities, 25 and it regulates survival and differentiation of 
osteoblasts 30. 
Dr. Croce’s group was the first to present evidence for tumor suppressive functions of 
miR-16 in attempts to explain a role of 13q14 deletions in chronic lymphocytic leukemia 
(CLL). They found MIR-16-1 locus deletion and/or miR-16 down-regulation in about two-
third of all CLL cases 31. Indeed, knock-out of miR-16-1 locus in mice caused CD5-
positive B-cell malignancies with penetrance of ~25% 32. Curiously, knock-out of miR-
16-2 locus in mice caused CD5-positive B-cell malignancies with 100% penetrance 33. 
However, no reports of MIR-16-2 locus deletion in human CLL can be found. One 
explanation may be a possible difference in the pattern of MIR-16-1 and MIR-16-2 loci 
expression between humans and mice. Nevertheless, all the mice data point toward 
tumor suppressive functions of both miR-16-1 and miR-16-2 loci. Noteworthy, no 
association between 13q14 deletion and miR-16 expression in human CLL was found 
34
. Our data, although obtained in human OS cells, gives a strong indication that down-
regulation the “passenger” miR-16-1* strand expression rather than the “lead” miR-16 
strand may be behind oncogenic effects of the MIR-16-1 locus deletion in CLL and other 
malignancies. 
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Although our data suggest strong tumor suppressive properties of miR-16, miR-16-1*, 
and miR-16-2*, obligatory knock-outs of neither miR-16-1 nor miR-16-2 loci were 
reported to cause osteosarcoma in mice 32, 33. It suggests that either additional 
oncogenic events are needed to cause OS in mice or miR-16, miR-16-1*, and miR-16-
2* expression down-regulation is involved in later stages of osteosarcomagenesis in 
mice or both possibilities together. Differences in mechanisms of osteosarcomagenesis 
between mice and humans are also possible. Predominant involvement of miR-16, miR-
16-1*, and miR-16-2* in later stages of osteosarcomagenesis, particularly, in OS 
metastasis and chemoresistance, seems to be highly possible in agreement with our 
data. Indeed, miR-16, miR-16-1*, and miR-16-2* affect mostly metastatic and 
chemoresistance properties of human OS cells at endogenous levels of expression. 
Our data about effects of synthetic miR-16, miR-16-1*, and miR-16-2* mimics on 
chemoresistance of human OS cells in vitro suggest a potential use of these mimics to 
improve the outcomes of the conventional OS chemotherapy. Noteworthy, miR-34a and 
miR-16 mimics-based drugs are already in clinical trial for treatment of different 
malignancies (reviewed in 3).  
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Figure Legends. 
Figure 1. Scheme of genomic loci encoding uuman miR-16, miR-16-1* and miR-16-
2*. (A) This is a schema depicting biogenesis of human miR-16, miR-16-1* and miR-16-
2* from two different genomic MIR-16 loci – MIR-16-1 and MIR-16-2. (B) Similarity 
between sequences of human miR-16-1* and miR-16-2* is shown. Similarity regions are 
highlighted in yellow. Human miR-16 sequence is also shown for comparison. Red 
letters indicate seed regions of presented microRNAs. Error bars represent standard 
errors of mean. 
 
Figure 2. Effects of human miR-16, miR-16-1* and miR-16-2* overexpression on 
OS cells survival and anchor-independent growth. (A) Overexpression of miR-16, 
miR-16-1* and miR-16-2* in HOS clones was assessed by SYBR green-based Real-
Time PCR. Expression of microRNAs in each sample was normalized to U44 
expression. MicroRNAs’ expression in the sample HOS-EPL, cl. 2 was taken as one. 
(B) A colony formation assay for HOS clones was conducted in four replicates in 10cm 
plates for each clone. One hundred fifty cells were seeded per each 10cm plate. Top – 
quantification of the assay; Bottom – representative pictures. (C) A soft agar colony 
formation assay for HOS clones was conducted in triplicates in wells of 6-well plates for 
each clone. One thousand cells were plated per a well of 6-well plate. Top – 
quantification of the assay; Bottom – representative pictures. (D) Overexpression of 
miR-16 and miR-16-2* in KHOS cells was assessed by SYBR green-based Real-Time 
PCR. Expression of microRNAs in each sample was normalized to U44 expression. 
MicroRNAs’ expression in the sample KHOS-EPL was taken as one. (E) A colony 
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formation assay for KHOS cells was conducted in four replicates in 10cm plates for 
each type of cells. One hundred fifty cells were seeded per each 10cm plate. Right – 
quantification of the assay; Left – representative pictures. (F) KHOS and HOS cells 
were infected with lentiviruses for overexpression of corresponding microRNAs at 
MOI=200. The same KHOS cells were applied in experiments shown on Figures 3A and 
3B (F) Each type of KHOS and HOS cells was subjected to the colony formation assay 
three days after infection. The colony formation assay was conducted in four replicates 
in 10cm plates for each type of cells. One hundred fifty cells were seeded per each 
10cm plate. EPL stays for empty puromycin lentivirus. Student’s t-test was applied 
everywhere with the exception of the figure (C) in order to estimate statistical 
significance. Rank-sum statistics was applied in the figure (C) in order to estimate 
statistical significance. Error bars represent standard errors of mean. ** – two-sided p-
value   0.01 for Student’s t-test; *** – two-sided p-value   0.001 for Student’s t-test; + – 
two-sided p-value ≤ 0.05 for Rank-sum statistics. 
 
Figure 3. Effects of human miR-16, miR-16-1* and miR-16-2* overexpression on 
OS cells apoptosis and chemoresistance. (A) and (B) KHOS cells were infected with 
lentiviruses for overexpression of corresponding microRNAs at MOI=200. The same 
KHOS cells were applied in the experiment shown on Figure 2F. Annexin V-FITC/PI 
staining was conducted for KHOS cells five days after infection. (A) Representative flow 
cytometry dot plots are shown. (B) Quantification of the apoptotic assay is shown. Cells 
in the right bottom quadrant were considered as early apoptotic cells and cells in the 
right top quadrant were considered as late apoptotic cells. Total percentages of 
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apoptotic cells are shown on the histogram. (C, D) HOS clones were subjected to 
cisplatin and doxorubicin resistance assays as described in “Materials and Methods”. 
Cytotoxicity was quantified by the XTT assay. (E) U2OS cells were transfected with 200 
pmols of a corresponding synthetic microRNA mimic. Ten thousand cells were seeded 
for the cisplatin resistance assay in 16 hours after transfections in wells of a 96-well 
plate. Cisplatin was added in 24 hours after seeding and the cisplatin resistance assay 
was conducted as described in “Materials and Methods”. Cytotoxicity was quantified by 
the XTT assay. EPL stays for empty puromycin lentivirus. Student’s t-test was applied in 
order to estimate statistical significance. Error bars represent standard errors of mean. * 
– two-sided p-value   0.05 for Student’s t-test; ** – two-sided p-value   0.01 for 
Student’s t-test; *** – two-sided p-value   0.001 for Student’s t-test. 
 
Figure 4. Effects of human miR-16, miR-16-1* and miR-16-2* sponges on U2OS 
cells cisplatin resistance. (A) A microRNA sponge is schematically depicted on the 
top of this picture. MiR-16, miR-16-1* and miR-16-2* binding sites and complementary 
interactions of these binding sites with corresponding microRNAs are shown below. 
Regions of complementary interactions between microRNAs’ binding sites and 
corresponding microRNAs are highlighted in yellow. (B) U2OS cells overexpressing 
microRNAs’ sponges were subjected to the cisplatin resistance assay as described in 
“Materials and Methods”. Cytotoxicity was quantified by the XTT assay. Student’s t-test 
was applied in order to estimate statistical significance. Error bars represent standard 
errors of mean. * – two-sided p-value   0.05 for Student’s t-test; ** – two-sided p-value 
  0.01 for Student’s t-test. 
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Figure 5. Effects of human miR-16, miR-16-1* and miR-16-2* overexpression on 
human OS cells tumorigenesis in NOD/SCID mice in vivo. (A)-(C) HOS clones 
overexpressing corresponding microRNAs were subcutaneously injected in NOD/SCID 
mice. Each HOS clone was injected in 5 NOD/SCID mice. Each mouse was injected in 
both, right and left, flanks (n = 10 per each HOS clone). HOS-EPL, cl. 2 and HOS-EPL, 
cl. 3, which are infected with the empty lentivirus, were applied as controls. (A) Time 
course of tumor growth for all HOS clones is presented. (B) Time course of tumor 
growth for HOS clones excluding the control HOS clones is presented. (C) 
Representative pictures of NOD/SCID mice with subcutaneous tumors are shown. 
(D),(E) NOD/SCID mice were injected in the right rare leg intratibially with HOS clones 
as described in “Material and Methods”. Five hundred thousand cells were used per 
each injection. Six mice were injected for each – HOS-EPL, cl. 2 (n=6) and HOS-miR-
16-1*, cl. 4 (n=6) clones. Five mice were injected for each – HOS-miR-16, cl. 3 (n=5) 
and HOS-miR-16-2*, cl. 6 (n=5) clones. Mice were open and all measurements were 
conducted on day 31 after injections. (D) Final measurements of tumors’ volumes are 
shown. (E) Representative pictures of NOD/SCID mice with intratibial tumors are 
shown. Blue arrows indicate the injected leg. (F),(G) NOD/SCID mice were 
subcutaneously injected with KHOS cells overexpressing corresponding microRNAs. 
Each NOD/SCID mouse was injected in both, right and left, flanks. Five hundred 
thousand KHOS cells were used per each injection. KHOS-EPL cells, which are 
infected with the empty lentivirus, were applied as a control. Two mice were injected 
with KHOS-EPL cells (n=4). Four mice were injected with KHOS-miR-16 cells (n=8). 
Three mice were injected with KHOS-miR-16-2* cells (n=6). (F) Time course of tumor 
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growth is presented. (G) Final measurements of tumors’ volumes are shown. Blue 
arrows indicate injected legs. Tumors’ volumes were measured as described in 
“Materials and Methods”. Subcutaneous injections were conducted as described in 
“Material and Methods”. EPL stays for empty puromycin lentivirus. Student’s t-test was 
applied everywhere with the exception of the figure (F) in order to estimate statistical 
significance. Rank-sum statistics was applied in the figure (F) in order to estimate 
statistical significance. Error bars represent standard errors of mean. * – two-sided p-
value   0.05 for Student’s t-test; ** – two-sided p-value   0.01 for Student’s t-test; *** – 
two-sided p-value   0.001 for Student’s t-test; # – one-sided p-value   0.05 for 
Student’s t-test; + – two-sided p-value ≤ 0.05 for Rank-sum statistics; ++ – two-sided p-
value   0.01 for Rank-sum statistics. 
 
Figure 6. Effects of human miR-16, miR-16-1* and miR-16-2* overexpression on 
invasion of HOS cells in vitro. Trans-well invasion in vitro assay for HOS clones 
overexpressing corresponding microRNAs was conducted as described in “Material and 
Methods”. Two hundred thousand cells were applied per a well. This assay was 
conducted in triplicates for each HOS clone. The assay was stopped and the invaded 
cells were counted in 4 hours. HOS-EPL, cl. 3, which is infected with the empty 
lentivirus, was applied as a control. (A) Quantification of the invasion assay is 
presented. (B) Representative pictures of fields with invaded cells are shown. Student’s 
t-test was applied in order to estimate statistical significance. ** – two-sided p-value   
0.01 for Student’s t-test. 
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